Role of inflammation in development of diabetic complications and commonly used inflammatory markers with respect to diabetic complications

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue SUPPL. 2, 2013, Pages 1-5

  Navale, Archana M ^a,b   Paranjape, Archana N ^a,b  

^a Parul Institute of Pharmacy and Research   (India)

^b PARUL UNIVERSITY   (India)

Author keywords

Anti inflammatory activity; Diabetic complications; Inflammation

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUTATHIONE PEROXIDASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; PADGEM PROTEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CELL DEATH; CELL INTERACTION; CELL PROLIFERATION; CYTOTOXICITY; DEGENERATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; HUMAN; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY HYPERTROPHY; MORBIDITY; NECROTIZING ARTERITIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POLYNEUROPATHY; RETINA EDEMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SODIUM RETENTION;

EID: 84878399557     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol dial Transplant 2005; 20: 2601-4.
2. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL, et al. Diabetic retinopathy. Diabetes Care 1998; 21:143-56.
3. Klein R, Klein BE. Diabetic eye disease. Lancet 1997; 350:197-204.
4. Zhang W, Liu H, Al-Shabrawey M, Caldwell RW, Caldwell RB. Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res 2011; 2:96-103.
5. Davidson JA, Ciulla TA, McGill JB, Kles KA, Anderson PW. How the diabetic eye loses vision. Endocrine 2007; 32:107-16.
6. Yuan SY. Protein kinase signaling in the modulation of microvascular permeability. Vascul Pharmacol 2002; 39:213-23.
7. Aveleira CA, Lin CM, Abcouwer SF, AmbrÓsio AF, Antonetti DA. TNF-α signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 2010; 59:2872-82.
8. Kowluru RA, Odenbach S. Role of interleukin-1β in the pathogenesis of diabetic retinopathy. Br J Ophthalmol 2004; 88:1343-7.
9. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999; 96:10836-41.
10. Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, et al. Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J 2003; 17:76-8.
11. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: Cause or consequence? Angiogenesis 2007; 10:149-66.
12. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macía M, et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis 1999; 33: 458-63.
13. Navarro JF, Mora C, Macía M, García J. Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis 2003; 42: 53-61.
14. Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S, Freeman BA. Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 1989; 257: L339-410.
15. Melcion C, Lachman L, Killen D, Morel-Maroger L, Striker GE. Mesangial cells, effect of monocyte products on proliferation, and matrix synthesis. Transplant Proc 1982; 14: 559-64.
16. Jones S, Jones S, Phillips AO. Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy. Kidney Int 2001; 59:1739-49.
17. Dalla Vestra M, Mussap M, Gallina P, Bruseghin M, Cernigio AM, Saller A, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: S78-S82.
18. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspect of interleukin 6. Immunol Today 1990; 11: 443-9.
19. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-42.
20. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993; 42: 450-6.
21. Navarro JF, Milena FJ, Mora C, León C, Claverie F, Flores C, et al. Tumor necrosis factor-α gene express on in diabetic nephrophathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 2005; 99 Suppl: 98-102.
22. Ortiz A, González-Cuadrado S, Bustos C, Alonso J, Gómez-Guerrero C, López-Armada MJ, et al. Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 1995; 8: 27-34.
23. McCarthy ET, Sharma R, Sharma M, Li JZ, Ge XL, Dileepan KN, et al. TNF-α increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 1998; 9: 433-8.
24. Dipetrillo K, Coutermarsh B, Gesek FA. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 2003; 284: F113-F121.
25. Kalantarinia K, Ais AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int 2003; 64: 1208-13.
26. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999; 34:818-23.
27. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-46.
28. Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005; 54: 2320-7.
29. Isaka Y, Akagi Y, Ando Y, Imai E. Application of gene therapy to diabetic nephropathy. Kidney Int 1997; 60 Suppl: 100-3.
30. Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol 2004; 15: 2637-47.
31. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 2009; 94:2157-63.
32. Satoh J, Yagihashi S, Toyota T. The possible role of tumor necrosis factor-α in diabetic polyneuropathy. Exp Diabesity Res 2003; 4: 65-71.
33. Said G. Inflammation in Diabetic Neuropathies. Eur Neurol Rev 2006; 6:73-6.
34. Michałowska-Wender G, Adamcewicz G, Wender M. Impact of cytokines on the pathomechanism of diabetic and alcoholic neuropathies. Folia Neuropathol 2007; 45:78-81.
35. Uçeyler N, Rogausch JP, Toyka KV, Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurology 2007; 69:42-9.
36. Saklani A, Parcha V, Dhulia I, Kumar D. Combined effect of Coccinia indica (Wight & Arn) and Salvadora oleoides (Decne) on blood glucose level and other risk factors associated with type 2 diabetes mellitus in alloxan induced diabetic rats. Int J Pharm Pharm Sci 2012; 4: 79-84.
37. Bernhardt V, D'souza JRT, Shetty A, Shantaram M, Vaswani R. Evaluation of neutrophil function, opsonising capacity and lymphocyte proliferation for risk of developing ischemic heart disease in type 2 diabetes mellitus patients. Int J Pharm Pharm Sci 2012; 4:318-22.
38. Huerta MG, Nadler JL. Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes. Curr Diabetes Rep 2002; 2:396-402.
39. Cumbie BC, Hemayer KL. Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. Vasc Health Risk Manag 2007; 3: 823-32.
40. Tsai SJ, Huang CS, Mong MC, Kam WY, Huang HY, Yin MC. Anti-inflammatory and Antifibrotic Effects of Naringenin in Diabetic Mice. J Agric Food Chem 2012; 60: 514-21.
41. Shi YC, Liao JW, Pan T. Antihypertriglyceridemia and Anti-Inflammatory Activities of Monascus-Fermented Dioscorea in Streptozotocin-Induced Diabetic Rats. Exp Dia Res 2011; doi:10.1155/2011/710635
42. Abd Ellah MR, Niishimori K, Goryo M, Okada K, Yasuda J. Glutathion peroxidase and glucose-6-phosphate dehydrogenase activities in bovine blood and liver. J Vet Med Sci 2004; 66:1219-21.
43. Xie Z, Wu X, Gong Y, Song Y, Qiu Q, Li C. Intraperitoneal injection of Ginkgo biloba extract enhances antioxidation ability of retina and protects photoreceptors after light-induced retinal damage in rats. Curr Eye Res 2007; 32:471-9.
44. Yue WF, Li GL, Liu JM, Sun JT, Sun HX, Li XH, et al. Anti-oxidation and immune responses in mice upon exposure to manganese superoxide dismutase expressed in silkworm larvae, Bombyx mori L. Cell Biol Int 2007; 31:974-8.
45. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
46. Fatehi M, Jafarzadeh M, Hassanabad ZF, Gholamnezhabad Z. The effect of Genistein, a tyrosine kinase Inhibitor on acute and chronic inflammation in Diabetic mice. DARU J Pharm Sci 2006; 14: 6-10.